Here is What Hedge Funds Think About Progenics Pharmaceuticals, Inc. (PGNX)
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much.
Progenics Pharmaceuticals Inc (PGNX)
This company is not actively trading or the ticker does belong to another company in our database now.
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Squarepoint Ops LLC Maxime Fortin (Cio) | 0 | $0 | 0% | |
| 2. | Ancora Advisors Frederick Disanto | 0 | $0 | 0% | |
| 3. | Highland Capital Management James Dondero | 0 | $0 | 0% | |
| 4. | Beryl Capital Management David Alexander Witkin | 0 | $0 | 0% | |
| 5. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.99 | 72,023 | $359,733.28 | 8,011,733 | 2019-09-09 | Filing | |
| $4.94 | 21,480 | $106,096.16 | 1,950,000 | 2019-09-09 | Filing | |
| $4.62 | 43,520 | $201,097.22 | 1,928,520 | 2019-09-05 | Filing | |
| $4.51 | 243,614 | $1,098,528.61 | 7,939,710 | 2019-09-04 | Filing | |
| $4.39 | 277,424 | $1,218,917.83 | 7,696,096 | 2019-09-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.55 | 150,000 | $1,432,500.00 | 6,997,269 | 2017-02-15 | Filing | |
| $9.68 | 150,000 | $1,452,000.00 | 7,147,269 | 2017-02-14 | Filing | |
| $9.70 | 100,000 | $970,000.00 | 7,297,269 | 2017-02-14 | Filing | |
| $9.70 | 50,000 | $485,000.00 | 7,397,269 | 2017-02-14 | Filing | |
| $9.70 | 52,600 | $510,220.00 | 7,447,269 | 2017-02-14 | Filing |
Institutional Investors' Holdings
News See All
Progenics Pharmaceuticals, Inc. (PGNX) Is Burning These Hedge Funds
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second ...
Here's What Hedge Funds Think About Progenics Pharmaceuticals, Inc. (PGNX)
There are several ways to beat the market, and investing in small cap stocks has historically been one of them.
Market Movers Today: Dropbox, Inc. (DBX), Micron Technology, Inc. (MU), New York & Company, Inc. (NWY), Geron Corporation (GERN), and More
(Reuters) - Dropbox Inc’s shares soared by as much as 50 percent in their first day of trading on Friday as investors rushed to buy into the biggest technology initial public offering in more than a...
Is Progenics Pharmaceuticals, Inc. (PGNX) a Good Stock to Buy?
Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required...
Portfolio Cuts Couldn't Stop HealthInvest From Buying Up These Stocks
HealthInvest Partners AB is a Stockholm-based fund management company co-founded by Carl Bennet and Anders Hallberg in 2006, which specializes in the healthcare sector.
Biotech Week In Review: Valeant, Progenics, Relistor and Vesneo – Valeant Pharmaceuticals Intl Inc (VRX) Progenics Pharmaceuticals, Inc. (PGNX)
Last week, the FDA had two major decisions to make regarding troubled drug maker Valeant Pharmaceuticals Intl Inc (NYSE:VRX).
Why Valeant, Progenics, Ryerson, Zafgen and TerraForm Are On The Move Today
U.S stocks headed back into the green on Wednesday, helped by strong earnings reports from the tech sector and a rebound in oil prices, driven by a slightly higher than expected decline in crude inventories...
Here's Why These Five Stocks Are Trending
Among the stocks trending today are McDermott International (NYSE:MDR), GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), Neustar Inc (NYSE:NSR), Progenics Pharmaceuticals, Inc.
Carbylan Therapeutics Inc (CBYL): Broadfin’s Latest Move and Market Smashing Q1 Returns Inside
To say Kevin Kotler’s Broadfin Capital had exceptional Q1 returns from its 11 long positions in companies valued at $1 billion or more would be a gross understatement.